Bioequivalence of Two Brands of Ciprofloxacin 750 Mg Tablets (Sarf® and Ciprobay®) in Healthy Human Volunteers

REFERENCES

• Hauschke D., Steinijans V.W., Diletti E.A. A Distribution-Free Procedure for the Statistical Analysis of Bioequivalence Studies. Int. J. Clin. Pharmacol. Ther. Toxicol. 1990; 28: 72–78
   PubMed Web of Science ®Google Scholar
• British National Formulary (BNF), 39th Ed. British Medical Association and the Royal Pharmaceutical Society of Great Britain. 2000
   Google Scholar
• Reynolds J.E.F. Martindale: The Extra Pharmacopoeia (electronic version). L DRUGEX® System, C.R. Gelman, B.H. Rumakc, T.A. Hutchinson. Micromedex Inc., Englewood, NJVol. 106, (expires Dec.2000)
   Google Scholar
• Product Information: Cipro(R), Ciprofloxacin. L DRUGEX®System, C.R. Gelman, B.H. Rumakc, T.A. Hutchinson. Micromedex Inc., Englewood, NJVol. 106, Bayer Pharmaceutical Division, West Haven, CT, 1997,(expires Dec.2000)
   Google Scholar
• Davis R., Markham A., Balfour J.A. Ciprofloxacin: An Updated Review of Its Pharmacology, Therapeutic Efficacy and Tolerability. Drugs 1996; 51: 1019–1074
   PubMed Web of Science ®Google Scholar
• Vance-Bryan K., Guay D.R., Rotschafer J.C. Clinical Pharmacokinetics of Ciprofloxacin. Clin. Pharmacokinet. 1990; 19: 434–461
   PubMed Web of Science ®Google Scholar
• Campoli-Richards D.M., Monk J.P., Price A., Benfield P., Todd P.A., Ward A. Ciprofloxacin. A Review of Its Antibacterial Activity, Pharmacokinetic Properties and Therapeutic Use. Drugs 1988; 35: 373–447
   PubMed Web of Science ®Google Scholar
• Bergan T. Extravascular Penetration of Ciprofloxacin. A Review. Diag. Microbial. Infect. Dis. 1990; 13: 103–114
   PubMed Web of Science ®Google Scholar
• Fabre D., Bressolle F., Gomeni R., Arich C., Lemesle F., Beziau H., Galtier M. Steady-State Pharmacokinetics of Ciprofloxacin in Plasma Form Patients with Nosocomial Pneumonia: Penetration of the Bronchial Mucosa. Antimicrob. Agents Chemother. 1991; 35: 2521–2525
   PubMed Web of Science ®Google Scholar
• Hoffken G., Lode H., Prinzing C., Borner K., Koeppe P. Pharmacokinetics of Ciprofloxacin After Oral and Parenteral Administration. Antimicrob. Agents Chemother. 1985; 27: 375–379
   PubMed Web of Science ®Google Scholar
• Gonzalez M.A., Moranchel A.H., Duran S., Pichardo A., Magana J.L., Painter B., Forrest A., Drusano G.L. Multiple-Dose Pharmacokinetics of Ciprofloxacin Administered Intravenously to Normal Volunteers. Antimicrob. Agents Chemother. 1985; 28: 235–239
   PubMed Web of Science ®Google Scholar
• Gonzalez M.A., Uribe F., Moisen S.D., Fuster A.P., Selen A., Welling P.G., Painter B. Multiple-Dose Pharmacokinetics and Safety of Ciprofloxacin in Normal Volunteers. Antimicrob. Agents Chemother. 1984; 26: 741–744
   PubMed Web of Science ®Google Scholar
• Sorgel F., Naber K.G., Jaehde U., Reiter A., Seelmann R., Sigl G. Brief Report: Gastrointestinal Secretion of Ciprofloxacin. Evaluation of the Charcoal Model for Investigation in Healthy Volunteers. Am. J. Med. 1989; 87(Suppl. 5A)62S–65S
   PubMed Web of Science ®Google Scholar
• Rohwedder R., Gegarn T., Thorsteinsson S.B., Scholl H. Transintestinal Elimination of Ciprofloxacin. Chemotherapy (Basel) 1990; 36: 77–84
   PubMed Web of Science ®Google Scholar
• Galicia I., Frias-Iniesta J., Carcas A.J., Soto A., Gomez E., Miranda E., Fernandez A., Montuenga C. Bioequivalence Evaluation of 2 Different Oral Formulations of Ciprofloxacin in Healthy Volunteers. Int. J. Clin. Pharmacol. Ther. 1998; 36(5)282–285
   PubMed Web of Science ®Google Scholar
• Anita S., Ming-Chung L., David V., Allen H.H. Oral Bioequivalence of Three Ciprofloxacin Formulations Following Single-Dose Administration: 500 mg Tablet Compared with 500 mg/10 mL or 500 mg/5 mL Suspension and the Effect of Food on the Absorption of Ciprofloxacin Oral Suspension. J. Antimicrob. Chemother. 1999; 43(Suppl. A)49–54
   PubMedGoogle Scholar
• FDA Guidelines. Bioequivalence Food and Drug Administration. Division of Bioequivalence,Office of Generic Drugs, Rockville, MD 1992, 1 July
   Google Scholar
• The United States Pharmacopoeia (USP) 24. The National Formulary XIX. United States Pharmacopoeial Convention, Rockville, MD, 2000, 240
   Google Scholar
• Shah V.P., Midha K.K., Dighe S., McGilveray I.J., Skelly J.P., Yacobi A., Layloft T., Viswanathan C.T., Cook C.E., McDowall R.D., Pitman K.A., Spector S. Conference Report: Analytical Method Validation: Bioavailability, Bioequivalence and Pharmacokinetic Studies. Pharm. Res. 1992; 9: 588–592
   Web of Science ®Google Scholar
• Win Nonlin. Professional Edition, Version 2.1. Pharsight Corp., 800 West Elcamino Real, Suite 200,Mountain View, , CA, 94040
   Google Scholar
• Chow C.S., Liu J.P. Design and Analysis of Bioavailability and Bioequivalence Studies. Marcel Dekker, New York 1992
   Google Scholar
• CPMC (Committee for Proprietary Medicinal Products). Note for Guidance: Investigation of Bioavailability and Bioequivalence. Working Party on the Efficacy of Medicinal Products. Brussels 1991
   Google Scholar